MA29032B1 - Produits composes contenant des epothilones et des inhibiteurs des proteines tyrosine kinases, et leurs utilisations pharmaceutiques - Google Patents

Produits composes contenant des epothilones et des inhibiteurs des proteines tyrosine kinases, et leurs utilisations pharmaceutiques

Info

Publication number
MA29032B1
MA29032B1 MA29923A MA29923A MA29032B1 MA 29032 B1 MA29032 B1 MA 29032B1 MA 29923 A MA29923 A MA 29923A MA 29923 A MA29923 A MA 29923A MA 29032 B1 MA29032 B1 MA 29032B1
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
epothilides
inhibitors
products containing
pharmaceutical uses
Prior art date
Application number
MA29923A
Other languages
English (en)
Inventor
Jerry Min-Jian Huang
Anandhi Ranganathan Johri
Ronald Richard Linnartz
Paul M J Mcsheehy
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36118322&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29032(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA29032B1 publication Critical patent/MA29032B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA29923A 2004-11-30 2007-05-22 Produits composes contenant des epothilones et des inhibiteurs des proteines tyrosine kinases, et leurs utilisations pharmaceutiques MA29032B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63183704P 2004-11-30 2004-11-30

Publications (1)

Publication Number Publication Date
MA29032B1 true MA29032B1 (fr) 2007-11-01

Family

ID=36118322

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29923A MA29032B1 (fr) 2004-11-30 2007-05-22 Produits composes contenant des epothilones et des inhibiteurs des proteines tyrosine kinases, et leurs utilisations pharmaceutiques

Country Status (29)

Country Link
US (2) US20080139587A1 (fr)
EP (1) EP1819331B1 (fr)
JP (1) JP2008521826A (fr)
KR (1) KR20070088653A (fr)
CN (1) CN101065127A (fr)
AT (1) ATE445398T1 (fr)
AU (1) AU2005312061B2 (fr)
BR (1) BRPI0518733A2 (fr)
CA (1) CA2584163A1 (fr)
CY (1) CY1110559T1 (fr)
DE (1) DE602005017181D1 (fr)
DK (1) DK1819331T3 (fr)
ES (1) ES2333348T3 (fr)
HK (1) HK1109059A1 (fr)
HR (1) HRP20100012T1 (fr)
IL (1) IL183138A (fr)
JO (1) JO2596B1 (fr)
MA (1) MA29032B1 (fr)
MX (1) MX2007006371A (fr)
NO (1) NO20073370L (fr)
NZ (1) NZ554552A (fr)
PL (1) PL1819331T3 (fr)
PT (1) PT1819331E (fr)
RU (1) RU2423980C2 (fr)
SI (1) SI1819331T1 (fr)
TN (1) TNSN07212A1 (fr)
TW (1) TW200630091A (fr)
WO (1) WO2006060331A1 (fr)
ZA (1) ZA200703196B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2503888A4 (fr) 2009-11-23 2015-07-29 Cerulean Pharma Inc Polymères à base de cyclodextrine pour une administration thérapeutique
WO2011090940A1 (fr) 2010-01-19 2011-07-28 Cerulean Pharma Inc. Polymères à base de cyclodextrine pour administration thérapeutique
EP2571525A4 (fr) 2010-05-18 2016-04-27 Cerulean Pharma Inc Compositions et procédés de traitement de maladies auto-immunes et autres
CN102134246A (zh) * 2011-01-06 2011-07-27 王文怡 一种埃博霉素衍生物及其制备和药物应用
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
US9738643B2 (en) 2012-08-06 2017-08-22 Duke University Substituted indazoles for targeting Hsp90
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
WO2017184956A1 (fr) 2016-04-22 2017-10-26 Duke University Composés et procédés de ciblage de hsp90
US10927083B2 (en) 2016-09-29 2021-02-23 Duke University Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en) 2016-09-29 2019-02-19 Duke University Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
WO2020023628A1 (fr) 2018-07-24 2020-01-30 Hygia Pharmaceuticals, Llc Composés, dérivés et analogues contre le cancer
WO2021185844A1 (fr) 2020-03-16 2021-09-23 Pvac Medical Technologies Ltd Utilisation d'une substance et composition pharmaceutique correspondante et traitements médicaux ou utilisations correspondants
WO2021233534A1 (fr) 2020-05-20 2021-11-25 Pvac Medical Technologies Ltd Utilisation d'une substance et composition pharmaceutique associée, et traitements médicaux ou utilisations associées
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2022047259A1 (fr) 2020-08-28 2022-03-03 California Institute Of Technology Circuits de signalisation de mammifère synthétiques pour la régulation de population cellulaire robuste
GB2617409B (en) 2022-04-27 2024-06-26 Cancertain Ltd Method for predicting responsiveness to therapy
WO2024030441A1 (fr) 2022-08-02 2024-02-08 National University Corporation Hokkaido University Procédés d'amélioration d'une thérapie cellulaire avec des complexes d'organites

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US20040034026A1 (en) * 2000-11-22 2004-02-19 Wood Jeannette M Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
AU2002308218B2 (en) * 2001-02-27 2005-11-10 Novartis Ag Combination comprising a signal transduction inhibitor and an epothilone derivative
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
ES2295428T3 (es) * 2001-10-25 2008-04-16 Novartis Ag Combinaciones que comprenden un inhibidor selectivo de ciclooxigenasa-2.
PL372070A1 (en) * 2002-06-10 2005-07-11 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20060094674A1 (en) * 2002-07-05 2006-05-04 Neel Benjamin G Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
EP1819331A1 (fr) 2007-08-22
DE602005017181D1 (de) 2009-11-26
PT1819331E (pt) 2009-11-30
NZ554552A (en) 2011-05-27
DK1819331T3 (da) 2010-01-04
AU2005312061B2 (en) 2009-09-03
PL1819331T3 (pl) 2010-03-31
IL183138A (en) 2011-03-31
TNSN07212A1 (en) 2008-11-21
CA2584163A1 (fr) 2006-06-08
JO2596B1 (en) 2011-02-27
US20110190312A1 (en) 2011-08-04
ATE445398T1 (de) 2009-10-15
HRP20100012T1 (hr) 2010-02-28
IL183138A0 (en) 2008-04-13
SI1819331T1 (sl) 2010-02-26
BRPI0518733A2 (pt) 2008-12-02
TW200630091A (en) 2006-09-01
RU2423980C2 (ru) 2011-07-20
NO20073370L (no) 2007-06-29
CN101065127A (zh) 2007-10-31
ES2333348T3 (es) 2010-02-19
WO2006060331A1 (fr) 2006-06-08
AU2005312061A1 (en) 2006-06-08
EP1819331B1 (fr) 2009-10-14
KR20070088653A (ko) 2007-08-29
JP2008521826A (ja) 2008-06-26
HK1109059A1 (en) 2008-05-30
MX2007006371A (es) 2007-06-20
RU2007124492A (ru) 2009-04-10
CY1110559T1 (el) 2015-04-29
US20080139587A1 (en) 2008-06-12
ZA200703196B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
MA29032B1 (fr) Produits composes contenant des epothilones et des inhibiteurs des proteines tyrosine kinases, et leurs utilisations pharmaceutiques
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
NO20081952L (no) Substituerte pyrazolforbindelser
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
EA200700142A1 (ru) Замещенные гетероциклом циклические производные мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
ATE400573T1 (de) 1h-imidazochinolinderivate als proteinkinaseinhibitoren
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
WO2006059234A3 (fr) Amides bicycliques comme inhibiteurs de kinases
MA31874B1 (fr) Inhibiteurs de bêta-lactamases
TW200801008A (en) Protein kinase inhibitors
WO2007115289A3 (fr) Combinaisons d'agents thérapeutiques destinées à traiter le cancer
EA201000879A1 (ru) Производные пиразола и их применение в качестве ингибиторов циклинзависимости киназ
WO2007150011A3 (fr) Inhibiteurs de prolyle hydroxylase
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
WO2006075095A3 (fr) Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 et pour le traitement du cancer
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2005074989A3 (fr) Combinaison (a) d'inhibiteur d'adn topoisomerase et (b) d'inhibiteur de iap
DK1233787T3 (da) Produkt, der inhiberer signaltransduktion fra heterotrimere G-proteiner, kombineret med et andet cancerbekæmpende middel til terapeutisk anvendelse i cancerbehandlingen
DK2094699T3 (da) Hidtil ukendte imidazolonderivater, fremstilling deraf som lægemidler, farmaceutiske præparater og anvendelse deraf som hæmmere af proteinkinaser, især cdc7
EA200800947A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ БЕНЗИМИДАЗОЛОВ И БЕНЗОТИАЗОЛОВ, СПОСОБ ИХ ПОЛУЧЕНИЕЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ Cmet
BRPI0515533A (pt) forma de dosagem estável de derivados de fenilalanina
CY1116251T1 (el) Συστηματα michael ως αναστολεις τρανσγλουταμινασων